1e
19
1
49
2
2
18
1b
1d
18
2f
63
1d
2 29
1d
25
Parul Agarwal, MD
88
63
Assistant Professor of Clinical Medicine (Hematology-Oncology)
28
80
3
5f
GI Cancer Quality and Care Innovation Leader, University of Pennsylvania
71
Medical Director, Perelman Center of Advanced Medicine- 2W
11
Department: Medicine
4
1
b
1d
46
Contact information
45
4
3
3
3
2
4
b
1f
45
PCAM 10 South Pavilion
48 Perelman Center for Advanced Medicine
Philadelphia, PA 19104
26
48 Perelman Center for Advanced Medicine
Philadelphia, PA 19104
2e
Office: 215-662-5858
30
a9
12
30
13
Education:
21 7 BA 1d (Medical Sciences) c
2a Boston University, 2011.
21 7 MD c
3d Boston University School of Medicine, 2015.
c
3
3
3
3
8d
Permanent link21 7 BA 1d (Medical Sciences) c
2a Boston University, 2011.
21 7 MD c
3d Boston University School of Medicine, 2015.
c
2 29
21
1e
1d
24
2b
29
27
23
19b Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, Klein AP, Laheru DA, Maxwell JE, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A.: Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prevention Research 17(7): 335-342, Jul 2024.
c0 Wilbur HC, Le DT, Agarwal P.: Immunotherapy of MSI Cancer: Facts and Hopes Clin Cancer Res 30(8): 1438-1447, Apr 2024.
18f Lau-Min KS, Marini J, Shah NK, Pucci D, Blauch AN, Cambareri C, Mooney B, Agarwal P, Johnston C, Schumacher RP, White K, Gabriel PE, Rosin R, Jacobs LA, Shulman LN.: Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine. JCO Oncol Pract Apr 2024.
d6 Chen SY, Heumann TR, Agarwal P, Zheng L.: The clinical application of immuno-therapeutics. Clinical Immuno-Oncology(2024), 237-288, Jan 2024.
12b Mohindroo C, Baydogan S, Agarwal P, Laheru D, Wright R, Prakash L, Mork ME, Klein ME, Maxwell J, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A.: Prevalence of germline variants in patients with pancreatic neuroendocrine tumors. ee Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL. 41, Jun 2023 Notes: "Poster Presentation" The American Society of Clinical Oncology Annual Meeting, Chicago, IL.
33f Agarwal P, Qi H, Munjal K, Gai J, Ferguson A, Parkinson R, Harrison J, Rodriguez C, Anders RA, Thompson ED, Burkhart R, He J, Narang A, De Jesus-Acosta A, Zheng L, Jaffee EM, George B, Laheru DA, Yarchoan M, Osipov A.: Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC). Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL. 41, Jun 2023 Notes: "Poster Presentation" American Society of Clinical Oncology Annual Meeting, Chicago, IL.
1b4 Chapin WJ, Agarwal P, DiCicco L, Palmer R, Cenou N, Chi Huang AC, Karasic TB.: Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers. Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL. 41(16), May 2023 Notes: "Poster Presentation" American Society of Clinical Oncology Annual Meeting, Chicago, IL. 14
1f0 Luke J, Sanborn RE, Rodón J, Patel M, Agarwal P, Friedman E, Peterson C, Kelley H, Wright E, Danaee H, Sun H, Barth C, Reilly T, Redig AJ, Friedman C.: Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors. Cancer Res. American Association for Cancer Research Annual Meeting, Orlando, FL. 83(8), Apr 2023 Notes: "Poster Presentation" At AACR Annual Meeting 2023 43 https://doi.org/10.1158/1538-7445.AM2023-CT251.
158 Christenson ES, Lim SJ, Durham J, De Jesus-Acosta A, Bever K, Laheru D, Ryan A, Agarwal P, Scharpf RB, Le DT, Wang H.: Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Cancer Res Commun 2(11): 1418-1425, Nov 2022.
2c
7
1d
1f
Selected Publications
1df Agarwal P, Guo M, Munjal K, Qi H, Parkinson R, Ferguson A, Mitchell C, Harrison J, Anders RA, Thompson ED, Wang H, De Jesus A, Zheng L, He J, Burkhart R, Narang A, George B, Jaffee EM, Yarchoan M, Laheru D, Osipov A.: A phase II study of neoadjuvant GVAX and cyclophosphamide combined with nivolumab and SBRT followed by surgery in borderline resectable pancreatic adenocarcinoma. Clin Cancer Res May 2025.19b Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, Klein AP, Laheru DA, Maxwell JE, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A.: Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prevention Research 17(7): 335-342, Jul 2024.
c0 Wilbur HC, Le DT, Agarwal P.: Immunotherapy of MSI Cancer: Facts and Hopes Clin Cancer Res 30(8): 1438-1447, Apr 2024.
18f Lau-Min KS, Marini J, Shah NK, Pucci D, Blauch AN, Cambareri C, Mooney B, Agarwal P, Johnston C, Schumacher RP, White K, Gabriel PE, Rosin R, Jacobs LA, Shulman LN.: Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine. JCO Oncol Pract Apr 2024.
d6 Chen SY, Heumann TR, Agarwal P, Zheng L.: The clinical application of immuno-therapeutics. Clinical Immuno-Oncology(2024), 237-288, Jan 2024.
12b Mohindroo C, Baydogan S, Agarwal P, Laheru D, Wright R, Prakash L, Mork ME, Klein ME, Maxwell J, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A.: Prevalence of germline variants in patients with pancreatic neuroendocrine tumors. ee Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL. 41, Jun 2023 Notes: "Poster Presentation" The American Society of Clinical Oncology Annual Meeting, Chicago, IL.
33f Agarwal P, Qi H, Munjal K, Gai J, Ferguson A, Parkinson R, Harrison J, Rodriguez C, Anders RA, Thompson ED, Burkhart R, He J, Narang A, De Jesus-Acosta A, Zheng L, Jaffee EM, George B, Laheru DA, Yarchoan M, Osipov A.: Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC). Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL. 41, Jun 2023 Notes: "Poster Presentation" American Society of Clinical Oncology Annual Meeting, Chicago, IL.
1b4 Chapin WJ, Agarwal P, DiCicco L, Palmer R, Cenou N, Chi Huang AC, Karasic TB.: Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers. Journal of Clinical Oncology, The American Society of Clinical Oncology Annual Meeting, Chicago IL. 41(16), May 2023 Notes: "Poster Presentation" American Society of Clinical Oncology Annual Meeting, Chicago, IL. 14
1f0 Luke J, Sanborn RE, Rodón J, Patel M, Agarwal P, Friedman E, Peterson C, Kelley H, Wright E, Danaee H, Sun H, Barth C, Reilly T, Redig AJ, Friedman C.: Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors. Cancer Res. American Association for Cancer Research Annual Meeting, Orlando, FL. 83(8), Apr 2023 Notes: "Poster Presentation" At AACR Annual Meeting 2023 43 https://doi.org/10.1158/1538-7445.AM2023-CT251.
158 Christenson ES, Lim SJ, Durham J, De Jesus-Acosta A, Bever K, Laheru D, Ryan A, Agarwal P, Scharpf RB, Le DT, Wang H.: Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma Cancer Res Commun 2(11): 1418-1425, Nov 2022.
2c